Asahi Kasei Pharma Corp - Company Profile
Powered by 
All the data and insights you need on Asahi Kasei Pharma Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Asahi Kasei Pharma Corp Strategy Report
- Understand Asahi Kasei Pharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, manufactures and markets diagnostic reagents, prescription drugs, and enzymes for diagnostic reagents. Its prescription drugs are used in the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, proteinuria in nephrotic syndrome, nocturia, and lupus nephritis, among others. Asahi Kasei Pharma offers assay kits for glycemic control and to detect prediabetes. The company’s pipeline products are intended for the treatment of chemotherapy-induced peripheral neuropathy, osteoporosis with high risk of fracture, Lupus nephritis and nephrotic syndrome, and severe sepsis with coagulopathy, among others. It has facilities in Shizuoka, and Nagoya, Japan. Asahi Kasei Pharma is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
1-1-2 Yurakucho, Chiyoda-ku, Tokyo, 100-0006
Website
www.asahikasei-pharma.co.jp
Telephone
81 3 66993600
Industry
Pharmaceuticals and Healthcare
Asahi Kasei Pharma Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Prescription Drugs | Bredinin |
| Enzymes for Diagnostic Reagents | Elcitonin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In August, the company licensed on the National Health Index for drug price standard and marketing of Empaveli for subcutaneous injection 1080 mg in Japan. |
| 2023 | Contracts/Agreements | In August, the company entered into a new agreement with AGC Biologics to produce clinical drug substance for antibody-based therapies. |
| 2023 | New Products/Services | In May, the company licensed on the National Health Index for drug price standard and marketing of Doptelet Tablet 20 mg in Japan. |
Competitor Comparison
| Key Parameters | Asahi Kasei Pharma Corp | Rohto Pharmaceutical Co Ltd | Dong-A Socio Holdings Co Ltd | Denka Seiken Co Ltd | GlaxoSmithKline (China) R&D Co., Ltd. |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | South Korea | Japan | China |
| City | Tokyo | Osaka-Shi | Seoul | Tokyo | - |
| State/Province | Tokyo | Osaka | - | Tokyo | - |
| No. of Employees | - | 7,176 | 273 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yoshikazu Aoki | President | Senior Management | - | - |
| Osamu Matsuzaki | Director; Executive Officer; Vice President | Senior Management | 2023 | - |
| Fumiaki Hamada | Senior Executive Officer; Director | Senior Management | 2023 | - |
| Yasuo Nakamura | Director; Executive Officer | Senior Management | 2023 | - |
| Masato Kashiwagi | General Manager - Corporate Planning & Coordination Division | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer